Justin F. Gainor, MD

Justin F. Gainor, MD, discusses the evolving lung cancer armamentarium.

Justin F. Gainor, MD, discusses a neoadjuvant use of biomarkers in nonmetastatic lung cancer.

Justin F. Gainor, MD, director of Targeted Immunotherapy, Massachusetts General Hospital, and assistant professor of medicine, Harvard Medical School, discusses neoadjuvant checkpoint blockade in non–small cell lung cancer (NSCLC).

Justin F. Gainor, MD, director of Targeted Immunotherapy, Massachusetts General Hospital, and assistant professor of medicine, Harvard Medical School, discusses subgroup analyses from the phase III PACIFIC trial in unresectable stage III non–small cell lung cancer (NSCLC).

Justin F. Gainor, MD, director of Targeted Immunotherapy, Massachusetts General Hospital, assistant professor of medicine, Harvard Medical School, discusses the phase III PACIFIC-2 trial in stage III non–small cell lung cancer (NSCLC).

Justin F. Gainor, MD, assistant professor of medicine, Harvard Medical School, attending physician, Massachusetts General Hospital, discusses the future of treatment for patients with EGFR-positive non-small cell lung cancer.